��������

Wendye Robbins is the President and CEO at Incendia Therapeutics, a clinical stage company focused on drugging novel targets in the tumor micro-environment. Robbins has served in various leadership roles at companies such as RAPT Therapeutics, Blade Therapeutics, and Limerick BioPharma, Inc. Wendye has a medical degree from The Medical College of Pennsylvania and has completed internships and fellowships in Internal Medicine, Anesthesiology, Critical Care Medicine, and Pain Medicine. Additionally, Robbins has also been involved in teaching and research at Stanford University School of Medicine.